Evidence map›Paper›PMID 41662485›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

A Spatiotemporally Controlled Nanoplatform for Photothermal BRD4 Degradation Enables Synergistic Cancer Immunotherapy.

Luyi Wang, Jiasha Wu, Rui Ji, Sufeng Qiang, Yulin Shen, Yan Zuo, Shiqin Jian, Siyao Liu, Fusheng Xu, Honggang Hu and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Luyi WangSchool of Medicine, Shanghai Integration and Innovation Center of Marine Medical Engineering, Shanghai University, Shanghai, China.
Jiasha WuDepartment of Chemistry, College of Sciences, Shanghai University, Shanghai, China.
Rui JiSchool of Medicine, Shanghai Integration and Innovation Center of Marine Medical Engineering, Shanghai University, Shanghai, China.
Sufeng QiangDepartment of Gynaecology and Obstetrics, School of Medicine, Shanghai East Hospital, Tongji University, Shanghai, China.
Yulin ShenSchool of Medicine, Shanghai Integration and Innovation Center of Marine Medical Engineering, Shanghai University, Shanghai, China.
Yan ZuoSchool of Medicine, Shanghai Integration and Innovation Center of Marine Medical Engineering, Shanghai University, Shanghai, China.
Shiqin JianSchool of Medicine, Shanghai Integration and Innovation Center of Marine Medical Engineering, Shanghai University, Shanghai, China.
Siyao LiuSchool of Medicine, Shanghai Integration and Innovation Center of Marine Medical Engineering, Shanghai University, Shanghai, China.
Fusheng XuSchool of Medicine, Shanghai Integration and Innovation Center of Marine Medical Engineering, Shanghai University, Shanghai, China.
Honggang HuSchool of Medicine, Shanghai Integration and Innovation Center of Marine Medical Engineering, Shanghai University, Shanghai, China.ORCID https://orcid.org/0000-0003-0577-3021
Xiaochun HuSchool of Medicine, Shanghai Integration and Innovation Center of Marine Medical Engineering, Shanghai University, Shanghai, China.

Funding

Fundamental Research Funds for the Central Universities 22120240343General Project of Pudong New Area Health Commission Health Science and Technology Project PW2024A-14National Natural Science Foundation of China 22477075
6 · The paper itself

Abstract

Conventional targeted protein degradation (TPD) via PROTACs is limited by E3 ligase reliance and a lack of spatiotemporal control, often causing systemic toxicity. Here, we report a photothermolysis-targeting conjugate (PTTAC) strategy for precise, light-activated degradation. We constructed a multifunctional theranostic nanoplatform (PCN-CuS-JQ/RGD) based on an MRI-visible, Fe-porphyrin MOF (PCN(Fe)) carrier, decorated with CuS photothermal agents, a BRD4 inhibitor (JQ1), and a tumor-targeting peptide (RGD). It executes a sophisticated step-wise delivery: 1) The RGD peptide facilitates active targeting to integrin-overexpressing tumor cells. 2) Upon internalization, the PCN(Fe) carrier decomposes within the cell, releasing smaller CuS-JQ/RGD units. 3) These units enter the nucleus and bind to the BRD4 protein. Under 1064 nm (NIR-II) laser irradiation, the localized photothermal effect generated by CuS induces the efficient degradation of BRD4. This PTTAC strategy not only inhibits tumor growth but also initiates a robust anti-tumor immune response by inducing immunogenic cell death (ICD) and downregulating PD-L1 expression. Crucially, in a bilateral tumor-bearing mouse model, our strategy demonstrated a powerful synergistic effect, significantly enhancing the efficacy of anti-PD-L1 immune checkpoint blockade therapy. This work presents a light-activatable degradation platform that achieves high tumor selectivity and potent immunotherapy, offering a promising new avenue for cancer treatment.

Indexed as

Cell Cycle ProteinsImmunotherapyNeoplasmsPhotothermal TherapyTranscription FactorsAnimalsBromodomain Containing ProteinsCell Line, TumorFemaleHumansMiceProteolysis Targeting ChimeraBRD4 protein, humanBromodomain Containing ProteinsCell Cycle ProteinsProteolysis Targeting ChimeraTranscription FactorsBRD4cancer immunotherapymetal‐organic frameworksphotothermal degradationtheranostics

Identifiers

PMID41662485
PMCPMC13088268

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.